Biological classification system (BCS); with a new perspective

Abstract
Biopharmaceutical classification system (BCS) is a drug development tool that is based on correlation of solubility with their bioavailability in human body and allows estimation of the contributions of three major factors, dissolution, solubility, and intestinal permeability, which affect oral drug absorption from immediate release (IR) solid oral products. This mini review gives an overview of BCS with special emphasis on concept, classification, extension and Biopharmaceutics drug disposition classification system (BDDCS) with brief idea on its applications.

Keywords: biopharmaceutical classification system, solubility, bioavailability, intestinal permeability, bioequivalence, product development, BDDCS

Introduction
The Biopharmaceutical Classification System (BCS) has increases the applicability and validity of drug solubility and permeability in terms of research. It is now well clear that drug absorption dependent on bioavailability and bioequivalence during the drug development process provided by U. S. Food & Drug Administration. The Biopharmaceutical classification system (BCS) is cogent tool for decision making during the phases of early drug development. The BCS was first devised in 1995 and became a standard in the regulation of bioequivalence of oral dosage forms. The BCS is a scientific framework that classifies a drug substance based on two parameters

a. Aqueous solubility
b. Intestinal permeability

If the absorption of the drug substance is permeation rate limited, the solubility of the drug substance will not be a governing parameter and so the in vitro dissolution study can be used to demonstrate the bioavailability (BA) or bioequivalence (BE) of the drug product through in vitro – in vivo correlation (IV–IVC). In BCS, each class has particularly designated rate-limiting step with possibilities for its modification so that the formulator can select and optimize a specific dosage form for the drug substance belonging to a particular class of BCS. Here we are mainly focusing on some of the new concepts of BCS.

Extension to BCS
Six class biopharmaceutical classification system
Bergstrom and co-workers have dividing the drugs into six classes considering solubility, permeability and calculated surface area which is the modified version of the BCS. The solubility was allotted as “high” or “low” and the permeability was classified as “low”, “intermediate,” or “high”. The non-polar portion of surface area of the molecule terminated in good permeability predictions. It is well suited for early development especially for optimization of the pharmacokinetic parameters.

Quantitative biopharmaceutical classification system (QBCS)
Apart from solubility of drug in the dissolution fluid dissolution can be dependent on the amount of drug present at the site of absorption (dose) considering this fact the quantitative BCS (QBCS) was designed by Rinaki and Co-workers. The classification was based on the solubility: dose ratio as main parameter. According to FDA guidance for the industry, August 2000, the highest dose strength of an immediate release product should be considered for study. The QBCS relies on a permeability and dose/solubility ratio. Permeability estimates, (P app that is the apparent permeability) were derived from Caco–2 cell studies and a constant intestinal volume content of 250ml was used to express the dose solubility ratio as a dimensionless quantity (q) (Table 1). Papp is the apparent permeability coefficient, which is the ratio of flux to concentration of drug in the donor compartment. Hence from it in–vitro tissue model can be used to predict in–vivo data. Apart from this the chiral conversion of the drug in the body is also considered by Gohel MC and Co-workers and gives Chirality based classification as given in Table 2.

Biopharmaceutics drug disposition classification system (BDDCS)
Chi Yuan Wu and co-workers in the 2005 proposed BDDCS considering factors like efflux transporters, food, absorptive transporters and renal or biliary routes of elimination on drug absorption and bioavailability. In the BDDCS, permeability is replaced by extent of metabolism and drugs are classified on the base of solubility and extent of metabolism. According to classification, if the drug is mainly eliminated by metabolism, then the drugs show high permeability. If the drug is mainly eliminated as unchanged drug by biliary or renal route, then the drugs show low permeability. Formerly, “Extensive metabolism” was defined as ≥50% metabolism of an oral dose in humans in vivo but now “extensive metabolism”
mean $\geq 70\%$ metabolism of an oral dose in vivo in humans whereas the “poor metabolism” mean excretion of $\geq 50\%$ of the dose unchanged (Figure 1).14,15

Table 1 Quantitative biopharmaceutical classification system

<table>
<thead>
<tr>
<th>BCS class</th>
<th>Papp*(cm/sec)</th>
<th>q*</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Papp $&gt; 10^{-5}$cm/sec</td>
<td>q$\leq 0.5$</td>
</tr>
<tr>
<td>II</td>
<td>Papp $&gt; 10^{-5}$cm/sec</td>
<td>q $&gt; 1$</td>
</tr>
<tr>
<td>III</td>
<td>Papp $&lt; 2 \times 10^{-6}$cm/sec</td>
<td>q$=0.5$</td>
</tr>
<tr>
<td>IV</td>
<td>Papp $&lt; 2 \times 10^{-6}$cm/sec</td>
<td>q $&gt; 1$</td>
</tr>
</tbody>
</table>

*Papp- apparent permeability and q- Dose/solubility.

Table 2 Chirality and BCS classification

<table>
<thead>
<tr>
<th>Class</th>
<th>Solubility</th>
<th>Permeability</th>
<th>Chiral conversion*</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>High</td>
<td>High</td>
<td>A High£</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B Low£</td>
</tr>
<tr>
<td>II</td>
<td>Low</td>
<td>High</td>
<td>A High</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B Low</td>
</tr>
<tr>
<td>III</td>
<td>High</td>
<td>Low</td>
<td>A High</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B Low</td>
</tr>
<tr>
<td>IV</td>
<td>Low</td>
<td>Low</td>
<td>A High</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B Low</td>
</tr>
</tbody>
</table>

*Chiral Conversion- an active form of drug is converted into an inactive form in blood stream. For racemic drugs, the fraction of dose of active enantiomer reaching the receptor site is more relevant for pharmacological response. £High- higher amount of active enantiomer is converted to inactive form. €Low- lower amount of active enantiomer is converted to inactive form.

Figure 1 Major route of drug elimination.

BCS – the future prospect

Since the birth of the BCS there are lot many revision of the BCS guidelines which will result in increased chances of applicability in development of drug with desired characteristics. A special emphasis should be given to the use of BCS in determination of the rate limiting step in the process of oral absorption during early phases of drug development and provision of important information to formulation scientists about the overall drug development process. BCS is not only a regulatory tool but also useful for the early development of molecule.16 Substantial differences of bio– waiver dossiers and respective assessments contribute to the impression that a common understanding is lacking on a successful use of the BCS concept to support.

Acknowledgements

None.

Conflict of interest

The author declares no conflict of interest.

References